Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Oates

Showing results (171-180 of 238) with videos related to

Pageof 24
Sort By:
British Journal of Cancer|February 25, 2009
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancerS Rao, N Starling, D Cunningham, et al.
British Journal of Cancer|July 22, 2004
Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancerS Rao, D Cunningham, T Price, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1987
Use of cross-correlation function to detect patient motion during SPECT imagingR L Eisner, T Noever, D Nowak, et al.
Digestive Diseases and Sciences|December 1, 1991
CP-66,948: an antisecretory histamine H2-receptor antagonist with mucosal protective propertiesJ P Hakkinen, W F Holt, C J Goddard, et al.
Human Mutation|March 25, 2018
A homozygous variant disrupting the PIGH start-codon is associated with developmental delay, epilepsy, and microcephalyAlistair T Pagnamenta, Yoshiko Murakami, Consuelo Anzilotti, et al.
Diabetes Care|August 29, 2006
Decline in neurophysiological function after 7 years in an adolescent diabetic cohort and the role of aldose reductase gene polymorphismsKeerthi Thamotharampillai, Albert K F Chan, Bruce Bennetts, et al.
Journal of Medicinal Chemistry|August 10, 2001
Sorbitol dehydrogenase inhibitors (SDIs): a new potent, enantiomeric SDI, 4-[2-1R-hydroxy-ethyl)-pyrimidin-4-yl]piperazine-1-sulfonic acid dimethylamideB L Mylari, P J Oates, D A Beebe, et al.
American Journal of Obstetrics and Gynecology|December 1, 1992
Aldose reductase inhibition prevents galactose-induced ovarian dysfunction in the Sprague-Dawley ratW R Meyer, M B Doyle, J A Grifo, et al.
American Journal of Physiology. Heart and Circulatory Physiology|September 29, 2000
Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injuryW R Tracey, W P Magee, C A Ellery, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2009
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trialsI Chau, A R Norman, D Cunningham, et al.
Pageof 24

Showing results (171-180 of 238) with videos related to

Sort By:
Pageof 24
British Journal of Cancer|February 25, 2009
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancerS Rao, N Starling, D Cunningham, et al.
British Journal of Cancer|July 22, 2004
Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancerS Rao, D Cunningham, T Price, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1987
Use of cross-correlation function to detect patient motion during SPECT imagingR L Eisner, T Noever, D Nowak, et al.
Digestive Diseases and Sciences|December 1, 1991
CP-66,948: an antisecretory histamine H2-receptor antagonist with mucosal protective propertiesJ P Hakkinen, W F Holt, C J Goddard, et al.
Human Mutation|March 25, 2018
A homozygous variant disrupting the PIGH start-codon is associated with developmental delay, epilepsy, and microcephalyAlistair T Pagnamenta, Yoshiko Murakami, Consuelo Anzilotti, et al.
Diabetes Care|August 29, 2006
Decline in neurophysiological function after 7 years in an adolescent diabetic cohort and the role of aldose reductase gene polymorphismsKeerthi Thamotharampillai, Albert K F Chan, Bruce Bennetts, et al.
Journal of Medicinal Chemistry|August 10, 2001
Sorbitol dehydrogenase inhibitors (SDIs): a new potent, enantiomeric SDI, 4-[2-1R-hydroxy-ethyl)-pyrimidin-4-yl]piperazine-1-sulfonic acid dimethylamideB L Mylari, P J Oates, D A Beebe, et al.
American Journal of Obstetrics and Gynecology|December 1, 1992
Aldose reductase inhibition prevents galactose-induced ovarian dysfunction in the Sprague-Dawley ratW R Meyer, M B Doyle, J A Grifo, et al.
American Journal of Physiology. Heart and Circulatory Physiology|September 29, 2000
Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injuryW R Tracey, W P Magee, C A Ellery, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2009
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trialsI Chau, A R Norman, D Cunningham, et al.
Pageof 24